China-based immune-oncology company Elpiscience is currently raising Series B funding which it hopes to complete within the next couple of months.
Darren Ji, chief executive of Elpiscience, told FinanceAsia that the amount of money it is looking for will be larger than the $55 million Series A funding which it raised from Lilly Asia Ventures, Hillhouse Capital and CDH Fund in December last year.
But the money is still not enough, according to Ji. He says that the company needs another two years fully to develop its products as Elpiscience wants to develop best-in-class treatment for the world.
Ji also...
¬ Haymarket Media Limited. All rights reserved.
